Not yet recruiting
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· Phase 1· Source
Not yet recruiting
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
NCT07857486· Phase 2· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Source
Not yet recruiting
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· Phase 2· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· Source
Recruiting
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· Phase 2· Source
Recruiting
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00· Phase 1· Source
Not yet recruiting
MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.
2025-522058-38-00· Phase 2· Source
Not yet recruiting
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
2025-523610-83-00· Phase 4· Source
Recruiting
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00· Phase 1· Source
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655· Phase 1· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Source
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360· Phase 2· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Source
Recruiting
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
NCT06225505· Source
Not yet recruiting
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2025-521090-14-00· Phase 2· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Source
Recruiting
Momelotinib in VEXAS syndrome
2024-519779-24-00· Phase 2· Source
Recruiting
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· Phase 3· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· Phase 2· Source
Recruiting
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
NCT07243470· Phase 1/2· Source
Recruiting
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un cancer du sein métastatique (TDXdose)
2025-522656-68-00· Phase 4· Source
Recruiting
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2024-514152-32-00· Phase 1· Source
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016· Phase 1· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960· Phase 1/2· Source
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· Phase 3· Source
Active, not recruiting
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors
NCT06660654· Phase 2· Source
Recruiting
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
2024-511435-10-00· Phase 1· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· Phase 3· Source
Active, not recruiting
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229· Phase 1· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Source
Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509· Phase 1· Source
Recruiting
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· Phase 3· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Source
Recruiting
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas
2024-514875-16-00· Phase 2· Source
Active, not recruiting
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789· Phase 3· Source
Recruiting
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680· Phase 1/2· Source
Not yet recruiting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients
NCT03212742· Phase 1· Source
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· Phase 1· Source
Recruiting
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
2023-509566-38-00· Phase 1/2· Source
Recruiting
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· Phase 3· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· Phase 1· Source
Active, not recruiting
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
NCT05753384· Phase 3· Source
Active, not recruiting
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
NCT05889221· Phase 2· Source
Active, not recruiting
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
NCT05826509· Phase 2· Source
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139· Phase 1/2· Source
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Source
Recruiting
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05751798· Phase 1/2· Source